Please assess the completion status of the following clinical trial:

Trial Title: Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ruptured saccular aneurysm confirmed by angiography and repaired by neurosurgical clipping or endovascular coiling~2. External ventricular drain in place~3. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 2-4 on the modified Fisher scale~4. WFNS grade 2, 3, or 4~Exclusion Criteria:~1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm~2. Angiographic vasospasm prior to randomization~3. Evidence of a cerebral infarction with neurological deficit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EG-1962 Group (Type: EXPERIMENTAL): * 1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~* Up to 21 days of placebo capsules/tablets
- Enteral Nimodipine Group (Type: ACTIVE_COMPARATOR): * 1 dose of intraventricular normal saline~* Up to 21 days of oral nimodipine capsules/tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).